Lal S, Malhotra S, Gribben D, Hodder D
Thorax. 1984 Nov;39(11):809-12. doi: 10.1136/thx.39.11.809.
Nedocromil sodium (FPL 59002) is a pyranoquinoline dicarboxylic acid that has been developed for the management of bronchial asthma. We report the results of a double blind group comparative trial in which the disodium salt of nedocromil delivered by pressurised aerosol and a placebo were compared in the management of patients with a diagnosis of bronchial asthma who entered the double blind period on a minimum dose of beclomethasone dipropionate. In almost all the assessments of clinical activity nedocromil sodium was shown to be more effective than placebo. These include improvements in diary card symptom scores, reduction in concomitant use of a bronchodilator aerosol, and patients' and investigators' assessments of efficacy. Unwanted effects were few and mild. No patients were withdrawn from the trial.
奈多罗米钠(FPL 59002)是一种吡喃喹啉二羧酸,已被开发用于治疗支气管哮喘。我们报告了一项双盲分组对照试验的结果,在该试验中,对诊断为支气管哮喘且在进入双盲期时使用最低剂量丙酸倍氯米松的患者,比较了通过压力气雾剂递送的奈多罗米二钠盐与安慰剂的治疗效果。在几乎所有临床活性评估中,奈多罗米钠都显示出比安慰剂更有效。这些评估包括日记卡症状评分的改善、支气管扩张剂气雾剂使用的减少以及患者和研究者对疗效的评估。不良反应少且轻微。没有患者退出试验。